title: Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
authors.forename: Peter
authors.initials: P
authors.lastname: Hokland
authors.forename: Finbarr
authors.initials: F
authors.lastname: Cotter
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers; D001856:Bone Marrow Examination / Q000379:methods; D002648:Child; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D003226:Congresses as Topic; D017277:Drug Approval; D005060:Europe; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000473:pathology*; D015337:Multicenter Studies as Topic; D018365:Neoplasm, Residual / Q000175:diagnosis*; D016133:Polymerase Chain Reaction / Q000379:methods; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers
keywords: acute leukaemia; flow cytometry; minimal residual disease; molecular diagnostics; regulation